Delivering unrivaled analytical performance and speed, the instruments are designed to uncover complex biological processes that could lead to advancements in precision medicine and significant insights for complex diseases like Alzheimer's and cancer. These Orbitrap innovations enhance Thermo Fisher's portfolio of industry-leading solutions, delivering a connected and powerful ecosystem that enables the success of customers in proteomics, biopharmaceutical development, and scientific research. "Continuing our strong track record of high-impact innovation, the Orbitrap Astral Zoom and Orbitrap Excedion Pro represent a significant leap forward in mass spectrometry, enabling researchers around the world to accelerate discovery and advance the pace of transformative scientific breakthroughs," said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher.